CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $1.157 million which beat the analyst consensus estimate of $360.417 thousand by 221.02 percent.